A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
IRIDEX Corporation (“IRIDEX”) is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Our propriety MicroPulse® Technology and Endpoint Management™ Technology are used for the treatment of glaucoma and retina disorders. Both technologies are offered as optional treatment modes in select laser consoles in addition to the standard continuous-wave (“CW”) treatment mode. They allow low-energy, subvisible, tissue-sparing laser therapy by different means: MicroPulse technology uses short, microsecond-long laser pulses that allow tissue to cool between pulses giving physicians finer control of thermal elevation to minimize tissue damage. Endpoint Management technology uses a delivery algorithm to titrate the laser energy.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 51M | 49M | 52M | 57M | 36M | 43M |
| Net Income | -5.1M | -8.9M | -9.6M | -7.5M | -6.3M | -8.8M |
| EPS | $-0.30 | $-0.54 | $-0.59 | $-0.47 | $-0.46 | $-0.64 |
| Free Cash Flow | -4.0M | -7.3M | -6.9M | -9.8M | -3.3M | -8.0M |
| ROIC | -8.5% | -365.4% | -23.0% | -43.8% | -34.0% | -38.8% |
| Gross Margin | 38.2% | 40.1% | 42.0% | 44.5% | 42.8% | 41.3% |
| Debt/Equity | 0.79 | 2.13 | 0.00 | 1.45 | 0.22 | 0.53 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -3.1M | -8.3M | -10M | -7.5M | -6.6M | -9.0M |
| Operating Margin | -6.0% | -17.1% | -19.3% | -13.2% | -18.1% | -20.7% |
| ROE | -108.7% | -153.4% | -100.5% | -43.8% | -36.4% | -38.8% |
| Shares Outstanding | 17M | 17M | 16M | 16M | 14M | 14M |
IRIDEX CORP passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 42.1%. At current prices, the estimated annualized return to fair value is +23.3%.
IRIDEX CORP (IRIX) has a 5-year average return on invested capital (ROIC) of -34.9%. This is below average and may indicate limited pricing power.
IRIDEX CORP (IRIX) has a market capitalization of $18M. It is classified as a small-cap stock.
IRIDEX CORP (IRIX) does not currently pay a regular dividend.
IRIDEX CORP (IRIX) operates in the Electromedical & Electrotherapeutic Apparatus industry, within the Healthcare sector.
IRIDEX CORP (IRIX) reported annual revenue of $49 million in its most recent fiscal year, based on SEC EDGAR filings.
IRIDEX CORP (IRIX) has a net profit margin of -18.3%. The company is currently unprofitable.
IRIDEX CORP (IRIX) generated $-7 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
IRIDEX CORP (IRIX) has a debt-to-equity ratio of 2.13. This indicates higher leverage, which may increase financial risk.
IRIDEX CORP (IRIX) reported earnings per share (EPS) of $-0.54 in its most recent fiscal year.
IRIDEX CORP (IRIX) has a return on equity (ROE) of -153.4%. A negative ROE may indicate losses or negative equity.
IRIDEX CORP (IRIX) has a 5-year average gross margin of 42.1%. This indicates decent pricing power.
The Ledger Terminal provides 13 years of financial data for IRIDEX CORP (IRIX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
IRIDEX CORP (IRIX) has a book value per share of $0.13, based on its most recent annual SEC filing.
No recent press releases.